DEFERRED INCOME

12 Months Ended

Dec. 31, 2012

Deferred Income [Abstract]

Deferred Income [Text Block]

Note 16. DEFERRED INCOME

Deferred income includes:

		December 31,
Dollars in Millions		2012		2011
Upfront, milestone and other licensing receipts		$	4,346	$	882
Atripla*	deferred revenue		339		113
Gain on sale-leaseback transactions			99		120
Other			65		88
Total deferred income		$	4,849	$	1,203
Current portion		$	825	$	337
Non-current portion			4,024		866

Upfront, milestone and other licensing receipts are amortized over the expected life of the product. See “Note 3. Alliances and Collaborations” for information pertaining to revenue recognition and other transactions including $3.5 billion of proceeds received from AstraZeneca related to the Amylin collaboration during the 2012.Deferred gains on several sale-leaseback transactions are amortized over the remaining lease terms of the related facilities through 2018. Deferred income amortization was $308 million in 2012, $173 millionin 2011and $137 million in 2010.